-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
US panel backs trendy peptides despite safety concerns
A US review panel on Thursday recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialized pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns.
The vote came as part of a two-day meeting of the panel tasked with considering whether seven total peptides should be added to the approved compounding list, which allows facilities to create custom drugs that will in turn be more accessible to the public.
As of Thursday afternoon, the panel had greenlit recommendations that bespoke pharmacies be allowed to produce the peptides BPC-157 and KPV.
Peptides are short chains of amino acids, which are the building blocks of proteins. They occur naturally in the body, but synthetic peptides are increasingly buzzy in the wellness industry as the key to an optimized life.
Peptide proponents have made sweeping claims about their benefits, ranging from glowing skin and muscle growth to brain health and wound healing.
There's scant to no clinical evidence supporting such promises.
Medical experts accused President Donald Trump's health chief Robert F. Kennedy Jr of packing the Food and Drug Administration advisory committee with people who have strong ties to the peptide industry, given his personal interest in the products that he says he has used.
The substances under review are among those that the administration of Trump's predecessor Joe Biden restricted from compounding, notably over a lack of human clinical trial data.
But that hasn't thwarted their popularity in many cases -- peptides can be purchased online from chemical suppliers "for lab use."
They are widely touted on social media among influencers, celebrities and those inclined to follow "wellness" trends, like Kennedy.
Proponents of increasing legal access to peptides, including the health secretary, argue that restricting them would only drive Americans deeper into the gray market.
The panel's 8-6 vote, with one abstention, to recommend the FDA's addition of BPC-157 and then KPV to the bulks list was at odds with the expert opinions of career scientists at the agency.
Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, told the committee she had voted no on BPC-157 "because of the lack of efficacy data" and "safety concerns."
Member Brian Lee also voted no on that peptide, saying: "I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes."
But they were outnumbered by panelists who voted in favor, with those members citing reasons including "the greater good" and "medical freedom" for their decisions.
- 'Weak evidence' vs commercial benefit -
Before considering each peptide, panelists heard presentations by FDA scientists who warned against recommending greater access, as well as public comment on both sides of the issue.
Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, urged against easing restrictions on all of the peptides, calling such an action "inconsistent" with FDA standards and dangerous to consumers.
He dubbed the burgeoning world of peptides as one of "pseudoscience and grift."
Interviewed afterward by AFP, Lurie said "what I think we're seeing is the demise of the advisory committee as a useful instrument in scientific decision-making under this administration."
"They stacked the committee with a group of people who, in the face of extremely weak evidence, voted in favor of these products anyway, and the FDA's efforts to balance that out weren't sufficient."
Telehealth company Hims & Hers was among those providing public comment.
"I'm not going to tell you that the evidence for BPC-157 is strong. It isn't, and I won't overclaim," said Anant Vinjamoori, the chief medical officer of the online medication provider's "Hims" branch.
"What I'd ask is that you not read thin as nonexistent."
He did note the company he works for would "benefit commercially" if it were allowed to offer peptides like BPC-157.
The panel recommendations are not binding, but the FDA historically has given them significant weight.
O.Brown--AT